OST-HER2 Regulatory Path Advanced for Phase 3 Trial
International regulators have aligned on study designs to expedite the potential global rollout of this cancer therapy.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Should pharmaceutical companies prioritize global regulatory cooperation to expedite the launch of new medical treatments?
OS Therapies reached a regulatory agreement with the U.S. FDA on a revised Phase 3 clinical study design for its cancer treatment, OST-HER2. The project will now proceed under the oversight of the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).
Why it matters
This alignment simplifies the global development pathway for OST-HER2 by allowing the manufacturer to harmonize requirements across multiple international jurisdictions. By utilizing established collaborative frameworks, the company aims to reduce regulatory friction and accelerate potential market access.
Regulatory bodies have finalized an amended Phase 3 trial protocol for OST-HER2 following a Type C Statistical Methods Meeting. This follows a track record of 29 products having successfully navigated the FDA approval process via Project Orbis since 2021.
The players
OS Therapies
A developer of cancer treatments based in Rockville, Maryland, and New York, New York, currently focused on the OST-HER2 program.
FDA
The U.S. federal agency responsible for evaluating the safety and efficacy of medical products and overseeing regulatory meetings.
MHRA
The U.K. government agency tasked with ensuring medical products meet safety and quality standards while leading international regulatory coordination.
The details
The collaboration leverages the Project Orbis framework to unify regulatory reviews across international borders. To bolster the trial, the company is integrating U.K. national patient registry data into a natural history database. This expanded dataset is intended to provide a more comprehensive baseline for monitoring patient outcomes as the treatment progresses toward commercial readiness.
Timeline
May 2019: Project Orbis was launched.
2021: Start of MHRA-led Project Orbis approvals.
August 2026: A Priority Review Voucher was sold for $220 million.
September 21, 2026: Update regarding regulatory alignment was published.
Mid Q4 2026: The Phase 3 clinical trial is expected to initiate in the U.K.
Health Landscape
The OST-HER2 program follows the established pattern of Project Orbis, which streamlines cancer drug approvals by coordinating reviews between international regulatory agencies. This shift reflects a broader trend toward harmonizing clinical trial data across global markets to expedite treatment availability.
This regulatory update indicates that a new investigational therapy is moving closer to clinical testing and potential public availability. Readers should discuss any questions regarding access to new cancer treatment trials with their oncologist to determine if they meet specific study criteria.
The takeaway
Harmonized regulatory pathways like Project Orbis serve to speed up the delivery of new cancer therapies to the global market. Patients and caregivers should remain in close contact with oncology specialists to track when new clinical trials open for recruitment in their region.
What happens next
The company expects to submit a Conditional Marketing Authorisation Application in the U.K. within the coming weeks. The initiation of the Phase 3 clinical trial is scheduled for mid Q4 2026, with commercial-ready drug product anticipated in 2027.
Further reading
For more information on current developments in oncology research, visit Cancer.
Live Poll
Should pharmaceutical companies prioritize global regulatory cooperation to expedite the launch of new medical treatments?
